Related Experiment Videos

[Supportive sepsis therapy: what is still valid today?]

M K Angele1, E Faist

  • 1Chirurgische Klinik und Poliklinik, Klinikum Grosshadern, Marchioninistrasse 15, 81377 München.

Insights

Despite new treatments, early source control and antibiotics remain key for septic patients. Protein C reduces mortality but increases bleeding risk, while AT III benefits only those not on heparin.

Area of Science:

  • Critical care medicine
  • Pharmacology
  • Infectious diseases

Context:

  • Sepsis management has seen limited success with various adjuncts.
  • Protein C (PROWESS) demonstrated significant mortality reduction in septic patients.
  • Bleeding complications associated with protein C restrict its use in surgical sepsis.

Purpose:

  • To review the efficacy and limitations of adjunct therapies in sepsis treatment.
  • To evaluate the impact of Protein C, AT III, and hydrocortisone on sepsis mortality.
  • To emphasize the foundational role of source control and antibiotic therapy.

Summary:

  • Protein C therapy (PROWESS) is the first adjunct to significantly lower sepsis mortality.
  • Antithrombin III (AT III) showed mortality benefit only in non-heparinized patients (KYBERSEPT).
  • Hydrocortisone's effect on survival remains unclear, despite reducing vasoactive agents.

Impact:

  • Highlights the need for risk-benefit assessment in sepsis adjuncts.
  • Reinforces the established efficacy of early source control and targeted antibiotics.
  • Informs clinical decisions regarding the use of Protein C and AT III in sepsis management.

Related Concept Videos